CD274 and cancer: They synthesized a dual-targeted delivery platform for temozolomide (TMZ), engineered to respond to both programmed death-ligand 1 (PD-L1)-expressing cancer cells and elevated ROS levels, with the goal of enhancing therapeutic outcomes in the hypoxic TME.